FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
GH Axis
This substance modulates the growth hormone axis. GH-axis stimulation carries risks including glucose intolerance, fluid retention, and theoretical concerns about sustained IGF-1 elevation.
Evidence visual
Ipamorelin evidence and risk matrix
intermediate researcher fit
Evidence
Tier B-C
Risk
high
Regulatory
not approved
WADA
S2
FDA
flagged
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Ipamorelin is a selective growth hormone secretagogue receptor (GHSR/ghrelin receptor) agonist. Originally profiled as more selective with less ACTH/cortisol/prolactin impact than earlier secretagogues, though 'minimal spillover' is dose- and context-dependent. FDA flagged ipamorelin acetate in its compounding safety risk context, citing immunogenicity/impurity characterization concerns including unnatural amino acids.
Decision path
Where Ipamorelin fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Ipamorelin belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
GHSR agonism stimulates GH release; originally profiled as more selective with less ACTH/cortisol/prolactin impact than earlier secretagogues.
subcutaneous, intravenous
Human PK/PD: infusion in nmol/kg over ~15 minutes across escalation steps.
GH-axis biomarker modulation. Body composition effects are speculative in consumer context.
GH pulse effects are acute; body composition claims are long-horizon and not well-established.
No established label contraindications (not approved).
Immunogenicity risk (FDA); impurity concerns with unnatural amino acids; glucose/cortisol axis concerns.
High uncertainty; glucose/cortisol axis monitoring concerns consistent with secretagogue class.
Cost at a glance
Typical cycle cost
$180.00
Estimated monthly
$60.00
Protocol style
8-12 week phase
Phase-based
Estimate confidence
High confidence
Assumes roughly 18 mg–36 mg per cycle, using 2 tracked affiliated listings.
Modeled as part of a longer GH-axis phase rather than a four-week test run.
Age, sex, and monitoring
Life-stage fit
Usually framed as a lower-friction GH secretagogue, but age still increases the burden of monitoring and risk review.
Best fit age ranges: 35-44, 45-54
55-64
Later-life use requires a more conservative standard because GH stimulation is harder to justify.
65+
Generally a poor fit in older adults unless a clinician-driven rationale exists.
Sex-specific note
Like other GH secretagogues, sex-specific data are weak, but reproductive caution is still warranted.
female
Avoid in pregnancy or active conception planning because reproductive safety is not established.
Monitoring burden
highSelective GH support still brings a meaningful monitoring burden because the axis being manipulated is the same one users usually underestimate.
Baseline labs and checks
IGF-1, fasting glucose or HbA1c, CMP
Follow-up cadence
Frequent early review, then periodic reassessment every few months.
Red flags
- edema
- glucose drift
- unexpected endocrine-type side effects
Known Interactions
GHRH analog + GHS-R agonist may produce additive GH release; multiple GH-axis peptides flagged for safety/characterization concerns.
GHRH analog + GHS-R agonist: additive GH release plausible.
Multiple GHS/GHS-R stimulation; FDA flags both for compounding risks/limited safety info.
Multiple GHS/GHS-R stimulation; limited stacking safety evidence.
MK-677 and ipamorelin both stimulate ghrelin-pathway signaling; redundancy and endocrine spillover risk rise.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Ipamorelin.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.